- WELCOME TO THE KAPER LAB -
THE KETAMINE ASSISTED PSYCHOTHERAPY EDUCATIONAL & RESEARCH PROGRAM
By Riverwoods Behavioral Health
We aim to develop cutting-edge, integrative, and evidence-based models of ketamine assisted psychotherapy (KAP) to improve clinical effect and health outcomes for patients; enhance standard of care delivery by clinicians and practitioners; and increase availability of empirical KAP programs in both medical and private practice settings.
WHAT DO WE DO?
The Ketamine Assisted Psychotherapy Educational and Research (KAPER) Program at Riverwoods Behavioral Health is committed to clinical research, education, and practice in the field of psychedelic medicine, specifically for the fast-acting antidepressant drug, ketamine. We primarily focus on developing novel ketamine assisted psychotherapy (KAP) interventions that bridge the mind, body, and brain to accelerate recovery, optimize cognitive function, and improve health outcomes across the neuropsychiatric continuum. These interventions are then tested in clinical trials, adapted and refined based on results, and ultimately implemented into real-world settings. Our team specializes in this process, following the NIH Stage Model for behavioral intervention development.
WHO DO WE SERVE?
We provide clinical trial services to patients with psychiatric and neurological disorders. This includes, but is not limited to, depression, anxiety, trauma, substance abuse (nicotine, alcohol, and opioids), process addiction (gambling, pornography, and eating disorders), and cognitive impairment (memory problems and dementia). All patients undergo a medical evaluation and psychological interview by research staff prior to participating in any study and receiving treatment.
Our team focuses on integrative, evidence-based approaches to ketamine assisted psychotherapy (KAP), as there are many factors that influence the mind, body, and brain — which are intimately connected — and should be considered when promoting health and wellbeing. Emerging research has also shown that adjunctive treatments to ketamine can enhance and sustain therapeutic effects to facilitate better health outcomes for patients. Studies have incorporated, for example, music, meditation, mindfulness, brain stimulation, and other medications (Abdallah et al., 2012; Dakwar et al., 2019; Mathew & Price, 2020; Veraart et al., 2021; Zhang et al., 2020; Zheng et al., 2019).
Our research is funded by federal and foundation grants, industry sponsors, and through the generosity of donors who wish to advance psychedelic medicine, brain science, and clinical care. If you wish to support our work, please contact Dr. Patricia Henrie-Barrus directly.
COLLABORATORS & FRIENDS
WHO MAKE THE RESEARCH POSSIBLE!